{"id":"W2098780362","doi":"10.1016/s0140-6736(03)14283-3","title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","year":2003,"lang":"en","type":"article","venue":"The Lancet","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":2614,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"AstraZeneca","keywords":"Candesartan; Medicine; Ejection fraction; Heart failure; Internal medicine; Cardiology; Hazard ratio; Placebo; Spironolactone; ACE inhibitor; Angiotensin II; Angiotensin-converting enzyme; Blood pressure; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}